Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Study and Identification of ADAM10 as Neuronal α-secretase in relation to Alzheimer’s disease

ADAMNEURON

With life expectancy increasing rapidly in our Western world, Alzheimer’s disease (AD), a progressive neurodegenerative disorder resulting in dementia, is becoming more common, however no cures or effective treatments are currently available. The neurotoxic amyloid-β (Aβ) peptide appears central to AD pathogenesis, and is generated by β- and γ...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Study of the aging-related changes of the gamma-secretase complex and evaluation to what extent those contribute to amyloid accumulation in sporadic Alzheimer’s disease

Γ-SECRETASE AGING

Alzheimer’s disease (AD) is the most common form of dementia. The main hallmark of AD is presence of the extraneuronal senile plaques composed of amyloid beta-peptide (Aβ). Aβ is produced when a transmembrane glycoprotein called Amyloid Precursor Protein (APP) is consecutively cleaved by two proteases: the γ-secretase and the β-secretase. γ...

Funding Programme
Start Date
End Date
Total Funding
€ 160 100
European Countries Involved

Super-sensitive detection of Alzheimer’s disease biomarkers in plasma by an innovative droplet split-and-stack approach

SensApp

The detection of biomarkers in body fluids is of great importance for disease early diagnosis. The clinical practice uses typically immunoassay methods (e.g. ELISA, Enzyme-Linked Immuno Sorbent Assay, and related techniques) for biomarker determination. Unfortunately, these techniques fail dramatically in a wide variety of cases where the...

Funding Programme
Start Date
End Date
Total Funding
€ 3 287 563
European Countries Involved

Support, Monitoring and Reminder Technology for Mild Dementia

SMART4MD

As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focussed on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of...

Funding Programme
Start Date
End Date
Total Funding
€ 3 834 555
European Countries Involved

Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms

SYNAPSING

Disrupted neuronal connectivity and synapse dysfunction can manifest clinically as a range of emotional, behavioural and cognitive symptoms that are common to, and often overlapping in, mental disorders (MDs) such as major depressive disorder, bipolar disorder and schizophrenia and neurodegenerative disorders (NDs) such as Alzheimers disease and...

Funding Programme
Start Date
End Date
Total Funding
€ 6 999 921
European Countries Involved

Synaptic Dysfunction in Alzheimer Disease

SyDAD

Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programmes from several big pharmaceutical companies. Increased collaboration between...

Funding Programme
Start Date
End Date
Total Funding
€ 3 846 736
European Countries Involved

Synaptic resilience in Tau-induced neurodegeneration

Hibernating_Synapses

Dementia is an enormous burden on society. Patients require life-long care and there is no cure or symptomatic treatment. At early phases, dementia is closely associated with synaptic degeneration and this correlates well with Tau pathology in >20 Tauopathies. Interestingly, historic observations in hamsters and squirrels show that when they enter...

Funding Programme
Start Date
End Date
Total Funding
€ 2 500 000
European Countries Involved

Targeted small-molecule Stabilisation of Protein-Protein Interactions

TASPPI

The goal of the TASPPI European Training Network (ETN) is the establishment of a highly interdisciplinary research and educational training platform for early stage scientists in the Chemical Life Sciences to overcome the inherent boundaries between academia and industry and to increase their employability in both areas. To this end we have teamed...

Funding Programme
Start Date
End Date
Total Funding
€ 3 342 323
European Countries Involved

Targeting Circadian Clock Dysfunction in Alzheimer’s Disease

TClock4AD

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes...

Funding Programme
Start Date
End Date
Total Funding
€ 3 811 636

The Ethics of Loneliness and Sociability

Ethics of Loneliness

Loneliness, which can be defined as the negative mental states (e.g. sadness, despair) that people experience when they feel that they do not have enough relationships, or not the right kinds of relationships, is a widespread phenomenon in many societies. Even prior to the current pandemic, surveys from Europe and North-America reported that 20 to...

Funding Programme
Start Date
End Date
Total Funding
€ 1 025 860
European Countries Involved

The Fast Periodic Visual Stimulation: a sensitive and objective approach to identify early cognitive markers of AD

ElectroMAD

Demographic analyses predict that one third of the 10 millions Belgian population in 2050 will be above 60 years of age. Since aging is the major risk factor for Alzheimer’s disease (AD), this increase in the proportion of seniors is closely linked to the increased prevalence of AD. With the advent of promising symptomatic treatment, it is critical...

Funding Programme
Start Date
End Date
Total Funding
€ 160 800
European Countries Involved

THE PRPC / PDK1 / TACE SIGNALING AXIS AT THE CROSS-ROAD OF SEVERAL AGGREGATE-PRONE PROTEIN-ASSOCIATED NEURODEGENERATIVE DISEASES

PrPC&PDK1

Neurodegenerative diseases such as Alzheimer's, Prion, Parkinson's diseases, Amyotrophic Lateral Sclerosis, Spino- cerebellar Ataxia and Fronto-temporal Dementia make up a group of pathologies with distinct etiologies and pathophysiological features characterized by the accumulation in the nervous system of abnormal proteins that are toxic for...

Funding Programme
Start Date
End Date
Total Funding
€ 1 461 047
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).